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Neuregulin 1 (NRG1) is suggested to promote the survival and maintenance of the
enteric nervous system (ENS). As deficiency in its corresponding receptor signaling
complex ERBB2/ERBB3 leads to postnatal colonic hypo/aganglionosis we assessed
the distributional and expressional pattern of the NRG1-ERBB2/ERBB3 system in the
human colon and explored the neurotrophic capacity of NRG1 on cultured enteric
neurons. Site-specific mRNA expression of the NRG1-ERBB2/3 system was determined
in microdissected samples harvested from enteric musculature and ganglia. Localization
of NRG1, ERBB2 and ERBB3 was determined by dual-label-immunohistochemistry
using pan-neuronal and pan-glial markers. Morphometric analysis was performed on
NRG1-stimulated rat enteric nerve cultures to evaluate neurotrophic effects. mRNA
expression of the NRG1-ERBB2/3 system was determined by qPCR. Co-localization
of NRG1 with neuronal or synaptic markers was analyzed in enteric nerve cultures
stimulated with glial cell line-derived neurotrophic factor (GDNF). The NRG1 system was
expressed in both neurons and glial cells of enteric ganglia and in nerve fibers. NRG1
significantly enhanced growth parameters in enteric nerve cell cultures and ErB3 mRNA
expression was down-regulated upon NRG1 stimulation. GDNF negatively regulates
ErbB2 and ErbB3 mRNA expression. The NRG1-ERBB2/3 system is physiologically
present in the human ENS and NRG1 acts as a neurotrophic factor for the ENS. The
down-regulation of ErbB3/ErbB2 in GDNF stimulated nerve cell cultures points to an
interaction of both neurotrophic factors. Thus, the data may provide a basis to assess
disturbed signaling components of the NRG1 system in enteric neuropathies.
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Introduction
Neuregulin 1 (NRG1), the best characterized member within the family of neuregulins, is
a pleiotrophic growth factor that has been implicated in various functions in the nervous
system e.g., nerve cell differentiation, neurite outgrowth and synapse formation (Falls,
2003; Mei and Nave, 2014). A variety of different isoforms are derived from the neuregulin
gene, which can be distinguished based on differences in their NH2-terminal regions. The
different NRG1 isoforms can be categorized into three groups: (i) type I NRG1 includes neu
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differentiation factor (NDF), the heregulins (HRGs) and
acetylcholine receptor inducing activity (ARIA); (ii) type II
NRG1 contains the glial growth factors (GGFs); and (iii) type III
NRG1 comprises the sensory and motor neuron-derived factor
(SMDF; Falls, 2003). NRG1 isoforms exert their effects through a
heterodimeric complex consisting of members of the epidermal
growth factor (EGF) receptor tyrosine kinases ErbB3/ErbB4 in
the heart and ErbB2/ErbB3 in neural crest cells (Britsch et al.,
1998; Garratt et al., 2000). All bioactive NRG isoforms contain an
EGF-like core domain (α or β) that is sufficient for activation of
ErbB receptor-tyrosine kinases (Buonanno and Fischbach, 2001).
Knock-out (KO) mice with targeted mutations of the Nrg1
gene show abnormalities in neural development of the central
nervous system (CNS) and peripheral nervous system (PNS)
in dependence on the deleted isoform, whereas NRG1 β
isoforms (NRG1βs) are crucial for normal neuromuscular system
development (Li et al., 2002; Falls, 2003).
The enteric nervous system (ENS) is one of the main divisions
of the nervous system and comprises a complex network of
ganglia and interconnecting nerve fibers that innervate the whole
gastrointestinal (GI) tract and thus orchestrates the functions of
the GI system (Furness, 2006). This neuronal network is arranged
in two major plexus, i.e., the submucosal and myenteric plexus
(MP; Wedel et al., 1999). Besides regulation of mucosal blood
flow or ion and water transport, one major function exerted
by the ENS is the regulation of GI motility, where the ENS
acts as initiator that transmits the signals to the enteric smooth
musculature via neurotransmitters and their receptors (Furness,
2012).
Consequently, ENS function can be impaired in enteric
neuropathies underlying intestinal motility disorders as
described for Hischsprung’s disease (HSCR; congenital colonic
aganglionosis) slow transit constipation or diverticular disease
(Knowles et al., 2009, 2010).
The importance of Nrg1 and its receptor signaling system
ErbB2/ErbB3 in the ENS became evident when Nrg1, ErbB3
or ErbB2 KO mice were investigated. ErbB3−/− mice exhibit
severe neuropathies with complete loss of glia (Riethmacher
et al., 1997) and reduced ganglia number in the duodenal gut
(Erickson et al., 1997). Conditional ErbB2/Nestin-Cre mutant
mice possess a dramatic reduction of enteric neurons and glia
in the colon and display a phenotype that mimics human HSCR
disease (Crone et al., 2003). In addition, a set of studies suggested
an involvement of NRG1 signaling in the development and
maintenance of the ENS. Nrg1 is expressed in mice and monkey
intestinal mucosa (Meyer et al., 1997; Zhao, 2013) and mice
enteric ganglia (Orr-Urtreger et al., 1993). The ErbB2/ErbB3
receptors are expressed in mouse neural crest cells that colonize
the gut during development and in adult intestinal epithelia
of both humans and mice (Paratore et al., 2002; Britsch,
2007).
However, a detailed characterization of the NRG1 system in
the human colonic neuro-musculature system responsible for GI
motility is still lacking. We therefore analyzed the site-specific
gene expression levels, localization and distribution of type I
NRG1 β1 (henceforth referred to as NRG1) and its receptors
ERBB2 and ERBB3 in the musculature and myenteric plexus
of the human colon. Furthermore we assessed the effect of
NRG1 on differentiation parameters of enteric nerve cell cultures
and analyzed the expression of Nrg1, ErbB2 and ErbB3 in
enteric nerve cells stimulated with NRG1 or glial cell line-derived
neurotrophic factor (GDNF), a typical neurotrophic factor for
the ENS. Finally, we analyzed the localization and distribution
of Nrg1 in enteric nerve cell cultures.
Materials and Methods
Human Tissue Source and Processing
Distal colonic segments were obtained from patients (n = 8,
mean age: 75 years, three female, five males) who underwent
partial colectomy for non-obstructing colorectal carcinoma.
Colonic motility disorders and anorectal evacuation were
excluded previously. Full-thickness specimens were harvested
at a safe distance (>5 cm) from the tumor and immediately
transferred for tissue processing to the laboratory. According
to the guidelines (Knowles et al., 2009) this procedure refers
to the common control tissue generation in gastroenterological
neuromuscular pathology. The study of human tissue received
approval from the Local Ethics Committee of the Faculty of
Medicine, Christian Albrechts University of Kiel, Germany
(B299/07).
After this surgical removal all of the specimens were
transferred into PBS (phosphate-buffered saline, pH 7.2) to allow
further dissection. Full-thickness tissue blocks (30mm× 10mm)
with rectangle form were pinned out flat on a cork plate by fine
needles without artificial stretching nor shortening, where the
longer border of the tissue block was oriented vertical to the gut
axis and thus corresponded to the cutting surface for histologic
sections. Thus, myocytes of the circular muscle (CM) layer were
cut along their longitudinal axis. For immunohistochemistry
the tissue blocks were transferred into paraffin wax and cut in
sections (6 µm) after fixation with 4% paraformaldehyde (in
PBS) for 24 h and dehydration. For RNA analysis, tissue blocks
were frozen in isopentane and stored at−70◦C.
Postnatal Myenteric Nerve Cell Cultures
Preparation of myenteric nerve cells was performed according
to the method described previously (Schäfer et al., 1997). Briefly,
after removing the small intestine from newborn Wistar rats
(postnatal day 2), the tunica muscularis was stripped from
the mucosa, incubated for 2 h at 37◦C in Hanks’ Balanced
Salt Solution (HBSS, Gibco Life Technologies/Invitrogen,
Karlsruhe, Germany) that is free of Ca2+- and Mg2+ and
completed with antibiotics and 1 mg/ml collagenase (SIGMA,
Munich, Germany). Afterwards, fragments of MP were
collected stereomicroscopically and incubated for at 37◦C
in trypsin/EDTA (0.125 mg/ml Gibco, Life Technologies,
Germany) for 15 min to dissociate the plexus. For stopping this
procedure trypsin/EDTAwas replaced with fetal calf serum (FCS,
Gibco, Life Technologies/Invitrogen, Karlsruhe, Germany).
The cells were triturated, counted and seeded on 12-well-
plates coated with poly-D-Lysin-(SIGMA)/Laminin (SIGMA,
Munich, Germany) at a density of 100.000 cells/ml. Cells were
incubated in defined medium consisting of Neurobasal A
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(Gibco, Life Technologies/Invitrogen, Karlsruhe, Germany)
and B27 supplement (Gibco, Life Technologies/Invitrogen,
Karlsruhe, Germany). Additionally, recombinant human
NRG1-β1 (Thr176-Lys246, EGF Domain; R&D Systems, MN,
USA) was added to a final concentration of 0 (control), 2
or 10 ng/ml or additionally for mRNA expression studies
recombinant rat GDNF (Peprotech, Hamburg, Germany). Cells
were cultured for 1 week where medium was changed every
second day.
Laser Capture Microdissection (LCM) and
Dissection of Colonic Myenteric Plexus and
Smooth Muscle Tissue
As described previously (Böttner et al., 2010), cryosections from
isopentane frozen tissue blocks (14 µm) were placed on slides
coated with polyethylene naphtalate (1 µm membrane, Carl
Zeiss MicroImaging GmbH, Göttingen, Germany) and regions
of interest were visualized by ultra-rapid (30 s) staining with
cresyl violet according to P.A.L.M. RNA Handling Protocols
(Zeiss MicroImaging, Göttingen, Germany). By inverse light
microscopy (Axiovert, Zeiss, Jena, Germany), the myenteric
ganglia were identified, laser-microdissected and collected by
laser pressure catapulting (P.A.L.M. Microlaser Technologies,
Bernried, Germany) in the lid of 0.5 ml reaction tubes. From each
sample 2mm2 ganglionic tissue was collected, dissolved in 200µl
RNA lysis buffer (PEQLAB, Erlangen, Germany) and stored at
−70◦C. Longitudinal and circular muscle tissue was collected
under stereomicroscopic control from cryosections (20µm)with
excluding the myenteric ganglia by carefully dissecting the tissue
with a scalpel. For each sample, the tissue of six cryosections
were collected, dissolved in 200 µl RNA lysis buffer (PEQLAB,
Erlangen, Germany) and storage was carried out at−70◦C.
Extraction of RNA and Reverse Transcription (RT)
Extraction of total RNA from human myenteric ganglia (MP),
circular (CM) and longitudinal muscle (LM) was performed
under usage of the peqGOLD MicroSpin Total RNA Kit
(PEQLAB, Erlangen, Germany). Myenteric nerve cell cultures
RNAwas isolated by the Nucleospin XS kit (Macherey andNagel,
Düren, Germany) according to the manufacturer’s instructions.
RNA was eluted in a volume of 15 µl H2O. Prior to reverse
transcription (RT), contaminating genomic DNA was digested
for 15 min at room temperature using 1.5 U of DNase I (Sigma-
Aldrich, Munich, Germany). RT was carried out in a total
volume of 30 µl containing 375 ng random hexamer primer
(GE Healthcare, Freiburg, Germany), 0.5 mM dNTPs (Promega,
Mannheim, Germany), 0.01MDTT, 1× reaction buffer, and 150
U Superscript II Reverse Transcriptase (Invitrogen, Karlsruhe,
Germany). Annealing, elongation, and denaturation were carried
out at 25◦C for 10 min, 42◦C for 50 min and at 70◦C for 15 min,
respectively.
Quantitative PCR (qPCR)
Quantitative PCR (qPCR) reactions were performed in 96 well
plates in duplicates. Each reaction (20 µl) contained 2 µl of total
cDNA, 900 nM primers, 225 nM hybridization probe and 1 ×
qPCR Master Mix Plus (Eurogentec, Cologne, Germany). qPCR
product accumulation was monitored by the ABI Prism 7700
cycler (TaqMan, Applied Biosystems, CA, USA) for 45 cycles.
Cycle contained a denaturation phase of 15 s at 95◦C and an
elongation phase of 1 min at 60◦C. The data were normalized
to the expression levels of the housekeeping gene hypoxanthine-
guanine phosphoribosyltransferase (HPRT), expressed as relative
mRNA expression and presented as mean ± SEM. Forward and
reverse primers and probes are listed below.
Primers Amplifying Human Sequences
NRG1 type I HRG β1 (NM_013956.3): forward primer:
5′-atggaggcggaggagctgta-3′, reverse primer: 5′-ttgcagtag
gccaccacaca-3′, probe: 5′-tgaccataaccggcatctgcatcgc-3′; ERBB2
(NM_004448.2): forward primer: 5′-ggaagtacacgatgcggagact-3′,
reverse primer: 5′-tctctttcaggatccgcatctg-3′, probe: 5′-tggagcc
gctgacacctagcgga-3′; ERBB3 (NM_001982.3): forward primer:
5′-tgccatcttcgtcatgttgaac-3′, reverse primer: 5′-tcaatataaacac
cccctgacagaa-3′, probe: 5′-agctccgcttgactcagctcaccga; HPRT
(NM_000194.2, house-keeping gene): forward primer:
5′-tgaacgtcttgctcgagatgtg-3′, reverse primer: 5′-ccagcag
gtcagcaaagaattt-3′, probe: 5′-tgggaggccatcacattgtagcc-3′.
Primers Amplifying Rat Sequences
Nrg1 type I Hrg-β1 (AY973244.1) forward primer: 5′-
ctaccagaagagggtgctgacaa-3′, reverse primer: 5′-gccgctgcttcttggtttt-
3′, probe: 5′-ctgctggtggtcggcatcttgtgtg-3′; Erbb2 (NM_017003.2):
forward primer: 5′-gctgctgcaggaaactgagttag-3′, reverse
primer: 5′-ccttccttagctccgtctcttttag-3′, probe: 5′-
ctgacgcccagcggagcaatgc-3′; Erbb3 (XM_006240755.1) forward
primer: 5′-cgaggagatgcgagctttcc-3′, reverse primer: 5′-
aaagcctgctgtgccagtaatc-3′, probe: 5′-ccccatgttcgttatgcccgcct;
hprt (NM_012583.2, house-keeping gene): forward primer: 5′-
cgccagcttcctcctcaga-3′, reverse primer: 5′-ggtcataacctggttcatcact-
3′, probe: 5′-ttttcccgcgagccgaccgg-3′.
Immunohistochemistry
Conventional Immunohistochemistry of NRG1,
ERBB2 and ERBB3 in Human Colonic Tissue
Immunoreactive signals were uncovered under usage of the
avidin-biotin-complex system (Vectastain Elite ABC Kit, Vector
Laboratories, Burlingame, CA, USA). To block the activity of
endogenous peroxidase paraffin embedded tissue sections were
incubated with 3% hydrogen peroxide briefly, rinsed in TBS-
buffer (TRIS-buffered saline; 10 mM TRIS, 50 mM NaCl, pH
7.4) and pretreated with citrate buffer (pH 6.0) in a 95◦C water
bath for 20 min. Thereafter, samples were incubated overnight
with a polyclonal rabbit-anti-NRG1 β1 antibody (HRG β1,
1:500, antibodies-online.com, Aachen, Germany; immunogen
sequence: KKPGKSELRINKAS), a polyclonal rabbit-anti-ERBB2
antibody (1:1000, antibodies-online.com, Aachen, Germany) or
a polyclonal rabbit-anti-ERBB3 antibody (1:2000 antibodies-
online.com, Aachen, Germany) respectively diluted in antibody
diluent (Invitrogen, Karlsruhe, Germany) and incubated with
biotinylated goat anti-rabbit IgG (1:400, DAKO, Hamburg,
Germany) for 45 min. After washing three times with
TBS, sections were incubated for 45 min with an avidin-
biotin-complex (Vectastain ABC Standard, Vector Laboratories,
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Burlingame, CA, USA) conjugated with horseradish peroxidase.
3,3′-diaminobenzidine (DAKO, Hamburg, Germany) was used
as chromogen. Sections were counterstained with Meyer’s
hematoxylin and negative controls were creating by omission
of the primary or secondary antibody. Analysis was carried out
with a light optical microscope (Nikon 6000, Nikon, Tokyo)
coupled to a digital camera (Digital Sight, Nikon, Tokyo). Data
acquisition was performed with NIS-Elements BR 3.2 software
(Nikon, Tokyo).
Dual-Label Immunohistochemistry of NRG1, ERBB2
and ERBB3 with the Pan-Neuronal Marker PGP 9.5 or
the Glial Cell Marker S100b
Pretreatment of paraffin embedded tissue sections was carried
out with citrate buffer (pH 6.0, 95◦C water bath) for 25 min
followed by overnight incubation with either rabbit-anti-HRG β1
(NRG1 1:200, antibodies-online.com, Aachen, Germany), rabbit-
anti-ERBB2 (1:500, antibodies-online.com, Aachen, Germany)
or rabbit-anti-ERBB3 antibody (1:1000 antibodies-online.com,
Aachen, Germany) respectively, diluted in antibody diluent
(Invitrogen, Karlsruhe, Germany) as primary antibodies. After
washing with TBS, sections were incubated with goat anti-
rabbit alexaFluor488 antibody, diluted in antibody diluent
(1:250, Invitrogen, Karlsruhe, Germany) as secondary antibodies
for 2 h at room temperature. Enteric neuron visualization
was realized by co-incubating the sections with mouse-anti-
PGP 9.5 (1:1000, Acris, Herford, Germany), enteric glia was
visualized by co-incubating the sections with mouse-anti-S100b
(1:1000, Merck Millipore, Billerica, MA, USA). Secondary
antibody incubation was carried out with goat-anti-mouse
AlexaFluor546 antibody (1:250; Invitrogen, Karlsruhe, Germany)
for 2 h at room temperature. DAPI staining of sections to
visualize cellular nuclei (Roche, Mannheim, Germany) was
carried out finally. Fluorescence signals were detected with a
fluorescence microscope (Axiovert 200M), (Zeiss, Göttingen,
Germany), linked to an Axiocam digital camera. Data were
analyzed with the Axiovision software (Zeiss, Göttingen,
Germany). Merging of immunoreactive signals was processed
by using the Zeiss co-localization tool (Zeiss, Göttingen,
Germany).
Immunocytochemistry of NRG1 in Enteric Nerve Cell
Cultures
Dual-label immunocytochemistry for NRG1 was performed
with PGP 9.5 or SNAP-25 in cells that were stimulated for
growth with 50 ng/ml GDNF (1 week). Cells fixing was realized
by incubating the specimens with 4% paraformaldehyde for
30 min. Cells were permeabilized for 10 min with methanol
and blocked with normal goat serum (1:10, DakoCytomation,
Glostrup, Denmark) for 30 min. Incubation with rabbit-
anti-HRG β1 (NRG1 1:200, antibodies-online.com, Aachen,
Germany) and either mouse anti-SNAP-25 antibody (1:10000,
LIFESPAN, Seattle, WA, USA) or mouse anti-PGP 9.5 antibody
(1:1000, Acris, Herford, Germany) for 1 h was performed,
followed by incubation with the secondary antibodies, goat
anti-rabbit-AlexaFluor488 (1:250, Invitrogen, Life technologies,
Carlsbad, CA, USA) and goat anti-mouse-AlexaFluor546 (1:250,
Invitrogen, Life technologies, Carlsbad, CA, USA). To visualize
cell nuclei specimens were counterstained with DAPI (Roche,
Mannheim, Germany). Analysis was carried out under usage
of a fluorescent microscope (Axiovert 200 M, Zeiss, Göttingen,
Germany) that was linked to an Axiocam digital camera
(Axiocam, Zeiss, Göttingen, Germany). The acquisition of data
was performed with the Axiovision software (Zeiss, Göttingen,
Germany).
Morphometric Analysis of Enteric Nerve Cell
Cultures
Immunocytochemistry in Enteric Nerve Cell Cultures
Cells were fixed for 30 min with 4% paraformaldehyde,
permeabilized for 10 min with methanol and treated for
10 min with 3% H2O2. After blocking of unspecific background
with normal goat serum (1:10, DakoCytomation, Glostrup,
Denmark) for 30 min, incubation with a mouse anti-PGP
9.5 antibody (1:1000, Acris, Herford, Germany) for 1 h
was performed, followed by incubation with a biotinylated
secondary antibody (goat anti-mouse IgG, 1:400) for 45 min
and treatment with an avidin-biotin-complex (Vectastain
ABC Standard, Vector Laboratories, Burlingame, CA, USA)
conjugated with horseradish peroxidase for 45 min. Antibody
binding was visualized with 3,3′-diaminobenzidine (DAKO,
Hamburg, Germany).
Technical Devices, Software
Morphometric analysis was carried out by using a light
optical microscope (Nikon 6000, Nikon, Tokyo) coupled to
a digital camera (Digital Sight, Nikon, Tokyo, Japan). Three
randomly chosen optical fields were recorded per cell culture
approach (200x magnification). Data acquisition on captured
images was performed with NIS-Elements BR 3.2 software
(Nikon, Tokyo, Japan), transferred into Excel 2010 (Microsoft
Corporation, Redmond, WA, USA) and further processed
for statistical analysis and data plotting (PrismTM, GraphPad,
San Diego, CA, USA).
Growth Parameters
Nerve fibers were retraced per image, the sum of nerve fiber
length was calculated in three randomly assigned optical fields
and the mean value was calculated. Data were presented as mean
of total nerve fiber length per optical field.
Branching points and ganglion-like aggregateswere counted in
three randomly assigned optical fields and the mean value was
calculated. Data were presented as mean branching points per
optical field and mean number of ganglion-like aggregates per
optical field. Ganglion-like aggregates are defined as a cluster of
neurons creating assemblage points, resembling enteric ganglia
(Figure 7). Experiments were carried out in nine replicates (2 and
20 ng/ml NRG1 vs. control).
Statistical Analysis
Data were analyzed by Mann–Whitney U test (PrismTM,
GraphPad, Sand Diego, CA, USA) followed by post hoc test with
the FDR method (false-discovery rate by using R 2.13.1 (R-Core-
Team, 2012). Differences were determined significant if p< 0.05.
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Results
Site-Specific Gene Expression of ERBB2 and
ERBB3 and their Corresponding Ligand NRG1 in
the Human Tunica Muscularis
In order to analyze the expression pattern of the NRG1-ERBB2/3
system in the human colon, we performed quantitative real
time PCR experiments of RNA isolated from CM, LM and MP,
separated per laser-capture microdissection (Figure 1). mRNA
expression of ERBB2, ERBB3 and their corresponding ligand
NRG1 was detected in all three tissues but differs in their
expression levels. Analysis of expression profiles revealed up to
sixfold higher expression levels of NRG1 (Figure 1A) in MP
compared to both muscle layers, that exhibited nearly the same
expression levels whereas ERBB2 (Figure 1B) exhibited more
pronounced expression in both muscle layers compared to MP.
mRNA expression of ERBB2 was up to sixfold higher in LM
and up to 17-fold higher in CM when compared to MP. In
contrast ERBB3 mRNA showed approximately equal expression
levels in MP and CM but twofold reduced expression level in LM
(Figure 1C).
Conventional Immunocytochemistry of NRG1,
ERBB2, and ERBB3 in the Human Tunica
Muscularis
Localization of NRG1, ERBB2, and ERBB3 in the human
tunica muscularis was determined by conventional
immunohistochemistry on colonic full-thickness sections,
using 3,3′-diaminobenzidine as cromogen. Consistent with the
findings of gene expression studies, NRG1 immunoreactivity
was detected in ganglia of the myenteric plexus (Figure 2A)
and circular musculature (Figure 2B), where signals was
distributed in neuronal somata large-area wide with a higher
density in the neuronal nucleus. NRG1 immunoreactivity
exhibited also strong signals in some but not all glial nuclei but
perinuclear signals were detected on most of the glial nuclei
(Figure 2A, arrowhead). The weakest signals in the myenteric
plexus were found in the neuropil. The circular musculature
exhibited faint NRG1 immunopositive signals (Figure 2B)
throughout the cell bodies, but also signals were detected in
some nuclei. ERBB2 immunoreactivity was also detected in both
the myenteric plexus (Figure 2C) and the circular musculature
(Figure 2D). Punctuate staining was observed throughout the
myenteric ganglia with higher density in neuronal somata
compared to the neuropil (Figure 2C, arrowhead). In the
circular musculature, the ERBB2 immunoreactive pattern
was similar to that demonstrated for NRG1 (Figure 2D),
but in difference it exhibited stronger area-wide signals,
compared to the NRG1 immunoreactive pattern. ERBB3
immunoreactivity was also found in the MP (Figure 2E).
Immunoreactive signals were detected in neuronal somata and
to a smaller extend throughout the ganglionic neuropil, however
in neuronal nuclei, ERBB3 immunoreactive was excluded.
ERBB3 immunoreactivity displayed also signals in the nerve
fibers within the circular musculature, but it was also found in a
few cell nuclei (Figure 2F).
Dual-Label Immunocytochemistry of NRG1,
ERBB2 and ERBB3 with the Pan-Neuronal
Marker PGP 9.5 and the Pan-Glial Marker S100b
in the Human Tunica Muscularis
To investigate the distributional expression pattern of NRG1,
ERBB2 and ERBB3 in neuronal structures, we performed dual-
label immunocytochemistry with PGP 9.5 as pan-neuronal
marker. For investigation the distribution of the NRG1-System
in glial cells co-localization experiments were performed with
S100b as pan-glial marker. NRG1 immunoreactive signals were
detected in the submucosal (Figures 3A–C) and myenteric
plexus (Figures 3D–F) in neuronal somata and nuclei. As
shown with conventional immunohistochemistry before, NRG1
immunoreactivity was also detected in the neuropil and as
perinuclear signals around a few glial nuclei. In addition in
the myenteric plexus NRG1 exhibited some strong rounded
signals, that did not co-localized with PGP 9.5, but co-
FIGURE 1 | Site-specific mRNA expression of Neuregulin 1 (NRG1), ERBB2 and ERBB3 in myenteric ganglia and smooth muscle layers of the adult
human colon. Analysis of site-specific mRNA expression profiles in microdissected myenteric plexus (MP), circular muscle (CM) and longitudinal muscle (LM)
revealed myenteric ganglia as the main source of NRG1 (A) whereas ERBB2 (B) is mostly expressed in the muscle layers. ERBB3 mRNA levels (C) are reduced in
LM compared to MP or CM where expression levels were approximately equal. Levels of mRNA were detected by reverse transcription (RT)-qPCR and expression of
genes of interest was normalized to the mRNA expression of the house-keeping gene HPRT. Data are shown as mean ± SEM, n = 6–8 per experimental group.
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FIGURE 2 | Localization of NRG1, ERBB2 and ERBB3 in the colonic
myenteric plexus and circular musculature of the adult human colon.
NRG1 immunopositive signals were identified in myenteric ganglia with robust
staining in neuronal somata and weaker signals in the surrounding neuropil
(A). Perinuclear staining (arrowhead) was detected on all glial nuclei (A). In the
circular musculature, smooth NRG1 immunoreactivity was observed as faint
signals with homogenous distribution (B). ERBB2 immunoreactivity in
myenteric ganglia (C) appeared to be less pronounced compared to the
surrounding neuropil but showed additional strong granular staining
(arrowheads) confined to cell somata. In the circular musculature, ERBB2
immunoreactivity (D) displayed slight signals similar to NRG1 and also with
uniform distribution. ERBB3 immunoreactivity was also found in myenteric
ganglia (E) accumulated in neuronal somata of singe neurons and also
observed area-wide throughout the ganglia as well as in nerve fibers running
within the CM layer (F). Blue color: haematoxylin counterstain. Bars: 20 µm.
localized with the pan-glial marker S100b, indicating, that
some, but not all glial cells express NRG1 (Figures 3J–L).
NRG1 immunoreactivity was also detected in the circular
musculature, with weaker signals in nerve fibers (Figures 3G–I,
arrowhead in I). Strong immunoreactivity was observed in some
muscle cell nuclei (Figures 3G–I, arrowhead in I). ERBB2
immunoreactivity was found as punctuate staining in the
neuronal somata of some, but not all myenteric or submucosal
neurons. The neuropil exhibited minor extend of punctuate
ERBB2 immunoreactivity (Figures 4A–F) and ERBB2 showed
slight signals in some glial nuclei (Figures 4J–L, arrowhead in
L). Some, but not all nerve fibers in the circular musculature
displayed ERBB2 immunoreactivity with punctuate pattern
(Figures 4G–I, arrowhead in I). In addition, some muscle
cells also exhibit ERBB2 immunoreactive signals (Figures 4G,I,
arrow). Strong ERBB3 immunoreactive signals, that co-localized
with the pan-neuronal marker PGP 9.5 were found area-
wide in submucosal and myenteric neuronal somata and the
neuropil (Figures 5A–F), whereas neuronal and glial cell nuclei
where generally excluded. Within the circular musculature,
ERBB3 co-localized with PGP 9.5, indicating ERBB3 presence
also in nerve fibers (Figures 5G–I). In addition, ERBB3
immunoreactivity co-localized to some extend with S100b
(Figures 5J–L) in the myenteric plexus, indicating that ERBB3
is also expressed in some glial cells.
Localization of Nrg1 in Enteric Nerve Cell Cultures
To assess the Nrg1 expression in vitro, we performed dual-
label immunocytochemistry on myenteric nerve culture with
PGP 9.5 as pan-neuronal marker for visualization of neuronal
somata and processes in single neurons (Figures 6A–C) and
with synaptosomal-associated protein 25 (SNAP-25), a synaptic
vesicle marker expressed in enteric ganglion-like aggregates
and neuronal processes (Figures 6D–F). PGP 9.5 displayed an
uniform labeling of neuronal elements (somata and processes)
of single myenteric neurons (Figures 6B,C), while NRG1
immunoreactivity was found as homogeneous signal in neuronal
somata (Figures 6A,C) and slight granular staining in nerve
processes (arrow) that all co-localize with PGP-9.5 (Figure 6C).
In myenteric ganglion-like aggregates, NRG1 co-localizes with
the vesicle marker SNAP-25 in the neuropil (Figure 6D,
arrow) and neuronal processes (Figure 6D, arrowhead). NRG1
immunoreactive signals were also found in some glial cells
(Figures 6D,F, dashed circle) and adjacent muscle cells.
Effects of NRG1 on Neuronal Network Formation of
Cultured Enteric Neurons
To assess the impact of NRG1 on neuronal network formation
and neurite outgrowth of enteric neurons, primary cultures were
treated with NRG1 (2, 20 ng/ml) and immunocytochemistry for
the pan-neuronal marker PGP 9.5 was performed. Nerve fiber
length, number of branching points and number of ganglion-
like aggregates resembling enteric ganglia were measured
(Figures 7A–C). After 1 week in culture, only sparse nerve fibers
could be identified in untreated cultures (control; Figure 1A),
whereas NRG1-treated cultures displayed a dose-dependent
increase of full nerve fiber length, with median nerve fiber length
of 550 µm for the controls, 2200 µm for cultures stimulated
with 2 ng/mL NRG1 and 3700 µm for cultures stimulated
with 20 ng/mL NRG1 (Figure 7D). NRG1 stimulated myenteric
cell culture developed neuronal networks dependent of NRG1
concentration as characterized by the number of branching
points per optical field with a median value of 7 for the controls,
50 for cultures stimulated with 2 ng/mL NRG1 and 92 for
cultures stimulated with 20 ng/mL NRG1 (Figure 7E). Ganglion-
like aggregates are also increased in number in dependence
of NRG1 concentration with median numbers of 2, 4 and 7
for controls, cultures stimulated with 2 ng/ml and cultures
stimulated with 20 ng/ml NRG1, respectively (Figure 7F) and
also exhibited in some cases a greater size (Figure 7C).
Effects of NRG1 and GDNF on Nrg1, ErbB2 and
ErbB3 mRNA Expression in Cultured Enteric Neurons
To investigate the effect of NRG1 and the well-known enteric
neurotrophic factor GDNF on gene regulation of the enteric
NRG1 system itself, mRNA expression ofNrg1, ErbB2 and ErbB3
were measured by RT-qPCR in rat enteric nerve cell cultures
treated with increasing concentrations of NRG1 of 2 ng/ml and
20 ng/ml and 50 ng/ml GDNF for 1 week (Figure 8). Neither
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NRG1 nor GDNF treatment regulated the Nrg1 mRNA enteric
nerve cultures (Figure 8A) and also no regulation of ErbB2 was
observed upon NRG1 treatment (Figure 8B). However, 50 ng/ml
GDNF administration significantly down-regulated ErbB2 up to
50% as compared to untreated controls (Figure 8B), and the
expression of ErbB3mRNAwas down-regulated up to 50% upon
both 2 ng/ml NRG1 and 50 ng/ml GDNF (Figure 8C), while
20 ng/ml NRG1 treatment had no significant effect (Figure 8C).
Discussion
Although expression and localization of NRG1 and its
corresponding receptors have been described in various
tissues and organs, their distribution in main components of
the colonic neuromuscular system has not been characterized
yet. Thus, we investigated the site-specific gene expression and
localization of NRG1 and ERBB2/ERBB3 in the human colon,
and further analyzed the neurotrophic capability of NRG1 on
cultured enteric neurons.
First, we showed differential expression and distribution
of NRG1 and its signaling system ERBB2/ERBB3 in the
human colonic tunica muscularis. Expression of NRG1 was
predominant in myenteric ganglia and NRG1 co-localized
with PGP 9.5 and the synaptic vesicle marker SNAP-25 in
enteric nerve cell cultures. ERBB2 was highest expressed in the
musculature. Treatment of enteric nerve cell cultures with NRG1
FIGURE 3 | Co-localization of NRG1 and PGP 9.5 or S100b in the human colon. NRG1 immunoreactivity (green) was detectable in submucosal (A,C) and
myenteric ganglia (D,F) visualized by the pan-neuronal marker PGP 9.5 (red, B,E), in the circular musculature (G–I) as well as in myenteric ganglia visualized with the
pan-glial marker S100b (red, K,L). NRG1 immunoreactivity in both submucosal and myenteric ganglia displayed predominant accumulation in gilal and neuronal
nuclei and neuronal somata but also exhibited faint signals in the neutropil. In the circular musculature, NRG1 signals were found in nerve fibers (I, arrowhead) and
also in some muscle cell nuclei. (I, arrow) Co-localization (yellow) of NRG1 and PGP 9.5 is shown in merged panels (C,F,I). Co-localization (yellow) of NRG1 and
S100b is shown in merged panel (L). Blue color: DAPI staining of nuclei. Bars (A–C) = 10 µm; (D–F): 20 µm; (G–I): 50 µm, (J–L): 20 µm.
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FIGURE 4 | Co-localization of ERBB2 and PGP 9.5 or S100b in the human colon. ERBB2 immunoreactivity (green) was observed in both submucosal (A,C)
myenteric ganglia (D,F) visualized by the pan-neuronal marker PGP 9.5 (red, B,E), in the circular musculature (G–I) as well as in myenteric ganglia visualized with the
pan-glial marker S100b (red, K,L). ERBB2 showed patchy and granular immunoreactive signals distributed in the neuronal somata and in the neuropil of the
submucosal and myenteric plexus and also exhibited faint signals in a few glial nuclei (L, arrowhead). In the circular musculature (G–I) ERBB2 immunoreactivity was
observed as inhomogeneous point-shaped signals with minor extend also in enteric nerve fibers (G,I, arrowhead in I) and muscle cells (G,I, arrow in I).
Co-localization (yellow) of ERBB2 and PGP 9.5 is shown in merged figures (C,F,I). Co-localization (yellow) of NRG1 and S100b is shown in merged panel (L). Blue
color: DAPI staining of nuclei. Bars (A–F): 20 µm; (G–I): 50 µm, (J–L): 20 µm.
significantly enhanced neuronal growth. GDNF treatment led to
down-regulation of ErbB2/ErbB3 mRNA expression in enteric
nerve cell culture.
Expression and Localization of NRG1, ERBB2
and ERBB3 in the Human Colon and Enteric
Nerve Cells
NRG1 is expressed mainly in the myenteric plexus. This
observation is in line with its abundant expression in the
CNS and points to its dominant role in neurotransmission,
neuroplasticity and glial-neuron interaction, as described before
(Marchionni et al., 1999; Mei and Xiong, 2008; Ting et al.,
2011). In the ENS, NRG1 type I mRNA transcripts were
previously found in the normoganglionic segment of infant
HSCR patients (Tang et al., 2012a) and in mouse embryos
(Orr-Urtreger et al., 1993). NRG1 immunoreactive signals were
previously detected in myenteric ganglia of mice (Crone et al.,
2003) and normoganglionic segement of infant HSCR patients
(Garcia-Barcelo et al., 2009), however tissue discrimination
in both mRNA and immunohistochemical studies was not
carried out, so that to our knowledge this study presents
the first data on site-specific NRG1 expression levels in
the colon.
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FIGURE 5 | Co-localization of ERBB3 and PGP 9.5 or S100b in the human colon. ERBB3 (green) was localized in enteric nerve cells visualized by the
pan-neuronal marker PGP 9.5 (red, B,E,H) of submucosal (A,C) and myenteric ganglia (D,F), in nerve fibers running within the circular musculature (G,I) as well as in
myenteric ganglia visualized with the pan-glial marker S100b (red, J,K). ERBB3 immunoreactive signals were accumulated in somata of single neurons and glial cells
and also observed area-wide throughout the ganglia (C,F,L). In the circular musculature (G–I) most ERBB3 immunoreactive signals were restricted to nerve fibers
(I, arrowhead). Co-localization (yellow) of NRG1 and PGP 9.5 is shown in merged figures (C,F,I). Co-localization (yellow) of NRG1 and S100b is shown in merged
figures (L). Blue color: DAPI staining of nuclei. Bars (A–F): 20 µm; (D–F, G–I): 50 µm, (J–L): 20 µm.
NRG1 protein was not only found in the neuropil and
neuronal somata of enteric neurons and glial cells, but also
in the neuronal and glial nucleus. Interestingly, some NRG1
isoforms contain putative nuclear targeting sequences (Holmes
et al., 1992), that translocate to the nucleus and alter gene
expression as shown for the type I NRG1 isoform heregulin
β1, whose translocation generates proapoptotic effects in breast
cancer cells (Li et al., 1996; Weinstein and Leder, 2000) and for
cysteine-rich domain isoforms of NRG1 in sensory neurons of
mice spinal ganglia (Bao et al., 2003). The authors demonstrated
that nuclear NRG1 represses the expression of several apoptotic
regulators, resulting in diminished death of neuronal cells
in vitro.
Both ERBB2 mRNA expression and immunoreactive signals,
that co-localize with neural structures, were only found to a
minor extent in the human myenteric plexus and as dense
punctate staining in the neuronal somata and neuropil, as
shown before in dorsal root ganglion (DRG) sensory neurons
(Pearson andCarroll, 2004). ERBB3 immunoreactivity was found
throughout neuronal somata and the neuropil and mRNA
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 September 2015 | Volume 9 | Article 360
Barrenschee et al. Neuregulin 1 and ERBB2/3 in ENS
FIGURE 6 | Localization of NRG1 in single myenteric neurons and ganglion-like aggregates. Dual-label immunocytochemistry for NRG1 (A–C) with PGP 9.5
(B) and NRG1 (D–F) with SNAP-25 (E) was performed after glial cell line-derived neurotrophic factor (GDNF) treatment (50 ng/ml) for 1 week. NRG1 co-localization
with PGP 9.5 was found in neuronal somata and processes of single enteric neurons (A,C). In nerve cell aggregates (D–F), NRG1 co-localization with SNAP-25
(F) was found in the neuropil (arrows) and neuronal processes (arrowhead in D). NRG1 immunoreactive signals was also found in some glial cells (D,F, dashed
circle). Blue color: DAPI staining of nuclei. Scale bars = 50 µm.
expression was similar to that observed in muscle cells. Despite
its function for neural crest differentiation and sympathetic
nervous system development (Britsch et al., 1998), the presence
of ERBB2 and ERBB3 immunoreactivity and mRNA expression
within the postnatal ENS indicates an involvement of the NRG1-
ERBB2/ERBB3 signaling system in maintaining and modifying
neuronal synapses during adulthood. This could be likely, since
it was recently found, that: (i) NRG1 upregulates the expression
of nAChR via the ErbB2/ErbB3-PI3K-MAPK signaling cascade
in adult autonomic ganglia (Kim et al., 2013); and (ii) NRG1
was observed to regulate the expression of nicotinic acetylcholine
receptors and formation of synapses (Yang et al., 1998) and to
induce the regulation and expression of post-synaptic GABA
receptors in the CNS (Flames et al., 2004).
Also in nerve fibers of the circular musculature of the
human colon, slight NRG1 immunoreactivity was found and
confirmatory to that, NRG1 immunoreactivity was detected
in enteric nerve fibers of single neurons and ganglion-like
aggregates. In the CNS, it is known, that neuronal axons express
NRG1 type III to regulate myelination (Nave and Salzer, 2006).
However, at the neuromuscular junction it is thought that
motoneuron-derived NRG1 type I acts on skeletal muscle fibers
to increase expression and clustering of cholinergic receptors
(Jo et al., 1995; Sandrock et al., 1997; Loeb et al., 2002). In the
PNS, NRG1 was found at synapses on phrenic α-motoneurons
(Issa et al., 2010) and concentrated in the postsynaptic subsurface
cistern of c-bouton inputs to α-motoneurons (Gallart-Palau
et al., 2014). In line with this, NRG1 co-localizes with the synaptic
vesicle marker SNAP-25 in enteric nerve cell cultures, pointing to
NRG1 expression in or near synaptic varicosities of the ENS.
Expression and Localization of NRG1, ERBB2
and ERBB3 in the Colonic Musculature
In the circular and longitudinal muscle layers NRG1 mRNA
expression were detected and NRG1 immunoreactivity in the
circular musculature could also be observed in some but not
all muscle cells. Similar to that, skeletal muscle cells express
NRG1 transcripts (Jaworski and Burden, 2006) and it is suggested
that muscle-derived NRG1 is involved in synapse-specific AChR
transcription (Rimer, 2003) and myotube formation (Kim et al.,
1999). However, its role in the smooth musculature remains
unclear.
The main source of ERBB2 mRNA expression was found in
the circular musculature, whereas ERBB3 was similarly expressed
in the myenteric plexus and the musculature. Confirmatory to
that, ERBBB2 displayed much more signals in the musculature
as in nerve fibers, however ERBB3 showed minor signals in
the musculature. Both, ERBB2 and ERBB3 expression was
shown before in muscle tissue e.g in human bladder (Borer
et al., 1999) and ErbB2 but no ErbB3 expression was found
in vascular smooth muscle cells (Iivanainen et al., 2003).
Regarding its diverse functions, it is likely, that ErbB2 has
additional roles in themusculature e.g., signaling elicited by other
factors, such as EGF (Carraway and Cantley, 1994), endothelin
(Daub et al., 1996), and cytokines, such as IL-6 (Qiu et al.,
1998).
In adult skeletal muscle and in C2 myoblasts and myotubes
ErbB2 and ErbB3 expression was previously shown, and it was
also reported, that NRG1 stimulates tyrosine phosphorylation
of ErbB2 when co-expressed with ErbB3. Thus, the authors
conclude, that ErbB3 is the predominant NRG1 receptor
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FIGURE 7 | Effects of NRG1 on nerve fiber length, number of ganglion-like aggregates and branching point quantity of cultured myenteric neurons.
Representative photographs of rat enteric nerve cells cultured for 1 week without NRG1 (A, control), with 2 ng/ml NRG1 (B) or with 20 ng/ml NRG1. (C) Control
cultures showed only limited outgrowth, branching of neurites and number of ganglion-like aggregates, whereas treatment of cultures with NRG1 exhibited an
enhancement of neurite outgrowth, increased number of neurite branches and ganglion-like aggregates. Morphometric analysis (D–F) confirmed the significant
increase of total neurite length (D), the number of neurite branches (E) and the number of ganglion-like aggregates (F) by NRG1 compared to controls. Bars:
100 µm. Visualization of neuronal structures was carried out by immunocytochemistry for the pan-neuronal marker PGP 9.5. Data are shown as mean ± SEM, n = 9
per experimental group, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. control.
in muscle cells and that a complex of ErbB2 and ErbB3
mediate NRG1 signaling in skeletal muscle (Jo et al., 1995).
However, NRG1-ERBB2/ERBB3 signaling in the smooth
musculature remains unclear, but its presence in the adult
human colon points to a putative signaling role in the smooth
musculature.
NRG1 as Neurotrophic Factor and Interaction
with other Neurotrophic Factors
In postnatal enteric nerve cultures, we observed, that NRG1
significantly enhanced total neurite length, branching and
number of ganglion-like aggregates suggesting a critical role for
NRG1 as a trophic factor not only in the developing ENS but also
during adulthood as shown before for the neurotrophic factor
GDNF (Böttner et al., 2013). In the CNS and PNS it is suggested,
that NRG1 signaling is also critical for the normal development
and distribution, since cortical interneurons depend on NRG1
for migration within the telencephalon toward to the cortex
(Flames et al., 2004) and cultured hippocampal neurons increase
neurite outgrowth, area, length, and branching when exposed
to NRG1 (Gerecke et al., 2004). In dorsal root ganglia explants,
NRG1 also regulates outgrowth of neurites and migration of
neurons (Liu et al., 2011).
For development and maintenance of the nervous system, it
is established, that two-way communication is needed between
neuronal cells and target cells (Korsching, 1993; Esper and Loeb,
2009). Reciprocal communications between neuronal NRG1 and
target-derived neurotrophic factors such as GDNF has been
uncovered in the CNS, where GDNF stimulate the expression
of NRG1 in motor neurons both in vitro and in vivo (Loeb and
Fischbach, 1997; Loeb et al., 2002) and locally applied GDNF
induced the rapid release of NRG1 from neurons and their
axons (Esper and Loeb, 2009). We could not find any effects on
the mRNA expression of NRG1 on postnatal enteric neurons,
however, we found a decrease of ErbB2 and ErbB3 mRNA
expression in response to GDNF treatment. Down-regulation of
ErbB3 mRNA expression in response to GDNF stimulation was
shown before in mouse enteric neural crest cells (Gui et al., 2013)
indicating a functional interaction between NRG1 and GDNF
signaling in the ENS. However, not only GDNF stimulation,
but also NRG1 exposition to enteric nerve cultures resulted in
decreased expression of ErbB3, an effect shown before in MCF7
cells, where ErbB3 down-regulation due to NRG1 stimulation
resulted in elevated steady-state levels of ErbB3 protein (Cao
et al., 2007). Thus, it seems likely that a GDNF-stimulated release
of NRG1 could be finally responsible for the observed down-
regulation of ErbB3 in GDNF treated enteric nerve cell cultures.
Relevance of the NRG1-ErbB Signaling System
for Enteric Neuropathies
Given the broad-range functions of the NRG1/ErbB signaling
system in the nervous system during development and
Frontiers in Cellular Neuroscience | www.frontiersin.org 11 September 2015 | Volume 9 | Article 360
Barrenschee et al. Neuregulin 1 and ERBB2/3 in ENS
FIGURE 8 | mRNA expression of NRG1, ERBB2 and ERBB3 in enteric nerve cell cultures in response to NRG1 or GDNF treatment. NRG1 mRNA
expression in enteric nerve cells were not regulated by NRG1 or GDNF stimulation (A), whereas NRG1 decreased mRNA levels of ERBB3 (C) and GDNF decreased
mRNA levels of both ERBB2 and ERBB3 (B,C). Enteric nerve cells were cultured for 6 days. Expression levels of the target gene were normalized to expression of
the house-keeping gene HPRT. Data are shown as mean ± SEM, n = 15–18 per experimental group, ∗p < 0.05, ∗∗p < 0.01 vs. control.
in the adult, NRG1 and ErbBs have been implicated in
several neuronal diseases of the CNS, e.g., schizophrenia
(O’Donovan et al., 2008), bipolar disorder (Goes et al.,
2009) or Alzheimer’s disease (Chaudhury et al., 2003), where
pathophysiological genetics such as NRG1- polymorphism (Go
et al., 2005) or abnormal protein or mRNA levels of NRG/ErbB
signaling components have been associated (Mei and Nave,
2014).
Interestingly, there is strong genetic and functional evidence
for a role of type I NRG1s in the pathogenesis of HSCR
(Tang et al., 2012a), a congenital disorder of the ENS,
that is associated with a complete loss of enteric neurons
(aganglionosis), since mutations in the NRG1 gene are
associated with this disease (Garcia-Barcelo et al., 2009).
NRG1 seems to contribute to both common and rare
HSCR variants (Luzón-Toro et al., 2012) and aberrant high
expression of type I NRG1 was observed in aganglionic
and normoganglionic segments of patients with HSCR (Tang
et al., 2012b), providing evidence for a pathological role of
dysregulated NRG1 in enteric neuropathies. Thus it is assumed
that distinct alterations of the NRG1-ErbB pathway do not
only lead to HSCR, that display complete aganglionosis, but
may also be associated with or contributed to other enteric
neuropathies probably characterized by a partial loss of enteric
neurons (hypoganglionosis), e.g., slow-transit constipation
or diverticular disease (De Giorgio and Camilleri, 2004;
Wedel et al., 2010), all disorders belonging to the group of
gastrointestinal neuromuscular diseases (GINMD; Knowles et al.,
2010).
Because an interaction of the NRG1 and GDNF signaling
system can be supposed in the ENS, the idea of an altered NRG1
system in some GINMDs is supported by the observation of
an altered GDNF system, as demonstrated so far not only for
HSCR (Butler Tjaden and Trainor, 2013) but also for diverticular
disease, where a lack of the neurotrophic factor GDNF and its
receptors RET and GFRα1 was recently observed (Böttner et al.,
2013).
In conclusion, we have demonstrated the presence of the
NRG1-ErbB2/ErbB3 system in main colonic neuromuscular
components and illustrated that NRG1 promotes growth and
differentiation of postnatal enteric neurons arguing for a role
of NRG1 in the maintenance of the ENS during postnatal
life. Further, down-regulation of ErbB receptor expression in
response to GDNF stimulation points to an interaction of
both signaling systems in enteric neurons. Thus, these findings
could serve as a basis to further investigate whether altered
NRG1-ErbB signaling may be linked to intestinal diseases
associated with enteric neuropathies. Possible new findings
could also contribute to more sophisticated diagnostics or
therapies.
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